Novartis AG to acquire Tourmaline Bio for $1.4 billion, $48.00 per share in cash. Acquisition agreement reached.Novartis has announced its acquisition of Tourmaline Bio at $48.00 per share in cash, amounting to a total equity value of around $1.4 billion.
